WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018160775) CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATORS AND CYP3A INHIBITORS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/160775 International Application No.: PCT/US2018/020336
Publication Date: 07.09.2018 International Filing Date: 28.02.2018
IPC:
A61K 31/56 (2006.01) ,A61K 31/497 (2006.01) ,A61P 43/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
56
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4965
Non-condensed pyrazines
497
containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
Applicants: CORCEPT THERAPEUTICS, INC.[US/US]; 149 Commonwealth Drive Menlo Park, California 94025, US
Inventors: BELANOFF, Joseph K.; US
Agent: WEBER, Kenneth A.; US
GAO, Chuan; US
SHURTZ, Kenneth R.; US
BORING, Landin F.; US
Priority Data:
62/465,77201.03.2017US
62/466,86703.03.2017US
Title (EN) CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATORS AND CYP3A INHIBITORS
(FR) ADMINISTRATION CONCOMITANTE DE MODULATEURS DE RÉCEPTEUR DES GLUCOCORTICOÏDES ET D'INHIBITEURS DE CYP3A
Abstract:
(EN) Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of a glucocorticoid receptor modulator (GRM) and steroidogenesis inhibitors, and by concomitant administration of a GRM and CYP3A inhibitors. The GRM may be, e.g., mifepristone; the CYP3A inhibitors or steroidogenesis inhibitors (collectively "inhibitors") may be, e.g., ketoconazole or itraconazole. Inhibitors may cause toxicity or other serious adverse reactions; concomitant administration of inhibitors with other drugs may increase the risk of such toxicity and adverse reactions due to the inhibitors and/or the other drugs. Applicant has surprisingly found that GRMs may be administered to subjects receiving inhibitors without increasing the risk of adverse reactions; for example, Applicant has found that mifepristone may be concomitantly administered with ketoconazole or itraconazole, providing safe concomitant administration of the GRM and ketoconazole or itraconazole. In embodiments, the GRM dose may be reduced during concomitant administration of the GRM with inhibitors.
(FR) La présente invention concerne des procédés de traitement de maladies, notamment le syndrome de Cushing et les cancers hormono-sensibles, par l'administration concomitante d'un modulateur de récepteur des glucocorticoïdes (GRM) et d'inhibiteurs de stéroïdogenèse et par l'administration concomitante d'un GRM et d'inhibiteurs de CYP3A. Le GRM peut être, par exemple, la mifépristone; les inhibiteurs de CYP3A ou les inhibiteurs de stéroïdogenèse (collectivement "inhibiteurs") peuvent être, par exemple, le cétoconazole ou l'itraconazole. Les inhibiteurs peuvent provoquer une toxicité ou d'autres réactions indésirables graves; l'administration concomitante d'inhibiteurs avec d'autres médicaments peut augmenter le risque d'une telle toxicité et de réactions indésirables dues aux inhibiteurs et/ou aux autres médicaments. Le demandeur a découvert de manière surprenante que les GRM peuvent être administrés à des sujets recevant des inhibiteurs sans augmenter le risque de réactions indésirables; par exemple, le demandeur a découvert que la mifépristone peut être administrée de manière concomitante avec du cétoconazole ou de l'itraconazole, permettant une administration concomitante sûre du GRM et du cétoconazole ou de l'itraconazole. Dans des modes de réalisation, la dose de GRM peut être réduite pendant l'administration concomitante du GRM avec des inhibiteurs.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)